COMPASS Pathways plc

NasdaqGS:CMPS Rapport sur les actions

Capitalisation boursière : US$318.8m

COMPASS Pathways Croissance future

Future contrôle des critères 0/6

COMPASS Pathways devrait augmenter ses bénéfices et son chiffre d'affaires de 9.8% et de 90.6% par an respectivement. Le BPA devrait croître de de 18.4% par an. Le rendement des capitaux propres devrait être -54.8% dans 3 ans.

Informations clés

9.8%

Taux de croissance des bénéfices

18.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices28.4%
Taux de croissance des recettes90.6%
Rendement futur des capitaux propres-54.8%
Couverture par les analystes

Good

Dernière mise à jour18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

Nov 01

Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision

Aug 19

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Jul 08

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

May 23

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

Apr 25

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Feb 08

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Dec 06
Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Booker again pushes for easier access to psychedelics for terminally ill patients

Oct 19

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

COMPASS Pathways And The Trillion Dollar Opportunity

Aug 11

COMPASS Pathways ADS Q2 2022 Earnings Preview

Aug 03

COMPASS Pathways names new CEO

Jul 19

Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy

Jun 30

We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Apr 28
We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Checking In On Compass Pathways

Mar 02

We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Dec 29
We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Compass Pathways: Psychedelics For Mental Health

Nov 23

Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy

Sep 17

COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

Sep 15
COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

Compass Pathways: Huge Growth Potential, But I'm Cautious

Jun 04

COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

May 25
COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

COMPASS Pathways raises $144M capital via equity offering

Apr 30

COMPASS Pathways launches public offering

Apr 27

We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate

Feb 08
We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate

Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront

Jan 01

Compass Pathways: Risky And Overvalued

Dec 18

What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?

Dec 18
What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:CMPS - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026N/A-154-141-1346
12/31/2025N/A-153-136-1347
12/31/2024N/A-157-116-1158
9/30/2024N/A-144-105-105N/A
6/30/2024N/A-139-100-100N/A
3/31/2024N/A-129-91-90N/A
12/31/2023N/A-118-97-97N/A
9/30/2023N/A-117-115-115N/A
6/30/2023N/A-102-117-117N/A
3/31/2023N/A-95-111-110N/A
12/31/2022N/A-92-106-105N/A
9/30/2022N/A-86-83-83N/A
6/30/2022N/A-84-78-77N/A
3/31/2022N/A-80-77-77N/A
12/31/2021N/A-72-68-68N/A
9/30/2021N/A-65-62-62N/A
6/30/2021N/A-66-62-62N/A
3/31/2021N/A-64-51-51N/A
12/31/2020N/A-60-42-41N/A
9/30/2020N/A-49-31-31N/A
6/30/2020N/A-38-22-22N/A
3/31/2020N/A-25-19-19N/A
12/31/2019N/A-20-18-18N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CMPS devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CMPS devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CMPS devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: CMPS ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: CMPS ne devrait pas générer de revenus l'année prochaine.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: CMPS devrait être non rentable dans 3 ans.


Découvrir les entreprises en croissance